Bluebird Bio Inc. has announced an update to its merger and acquisition transaction with Carlyle and SK Capital. The company has amended its agreement, providing stockholders with the option to receive either the original offer of $3.00 per share in cash plus a contingent value right of $6.84 per share in cash, contingent on achieving a net sales milestone, or a revised offer of $5.00 per share in cash. The transaction has received all necessary regulatory approvals and is expected to be finalized shortly after the tender offer deadline, which is set for May 29, 2025. Ayrmid Ltd. has confirmed it will not submit a competing proposal, solidifying the transaction with Carlyle and SK Capital as the sole option for Bluebird stockholders.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.